Patents by Inventor Xiaojiang Cui
Xiaojiang Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913022Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.Type: GrantFiled: January 25, 2018Date of Patent: February 27, 2024Assignee: Cedars-Sinai Medical CenterInventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano
-
Publication number: 20200332316Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: ApplicationFiled: June 30, 2020Publication date: October 22, 2020Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Xiaojiang Cui, Dhruv Sareen, Loren A. Ornelas
-
Publication number: 20200325544Abstract: In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of FOXC1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided. In other embodiments, methods for diagnosing metastatic breast cancer using the expression ratio of FOXC1/FOXA1 in a population of breast cancer tumor cells are provided. The methods also entail administering a treatment for metastatic breast cancer if the expression ratio of FOXC1/FOXA1 in the population of breast cancer tumor cells is elevated as compared to a control. Other embodiments provide methods for treating breast cancer with a proteasome inhibitor alone or in combination with a Wnt inhibitor in subjects with tumor cells expressing FOXC1 in a subject.Type: ApplicationFiled: February 21, 2020Publication date: October 15, 2020Inventors: Partha S. RAY, Sanjay BAGARIA, Xiaojiang CUI, Jinhua WANG
-
Patent number: 10738323Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: GrantFiled: July 11, 2014Date of Patent: August 11, 2020Assignee: Cedars-Sinai Medical CenterInventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
-
Publication number: 20200025764Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: February 26, 2019Publication date: January 23, 2020Inventor: Xiaojiang CUI
-
Publication number: 20200002671Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.Type: ApplicationFiled: January 25, 2018Publication date: January 2, 2020Applicant: Cedars-Sinai Medical CenterInventors: Ying QU, Xiaojiang CUI, Dhruv SAREEN, Armando E. GIULIANO
-
Patent number: 10253368Abstract: Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of ovarian cancers through generation of ovarian cancer disease signatures (OCDSs) that account for molecular heterogeneity present in gynecological cancers. An ovarian cancer fixed signature (OCFS) is described which relates to the core programming of disease development, in addition to an ovarian cancer stem cell (OCSC) signature. Development various disease signature, suggests personalized treatment strategies focused on molecular subtypes of gynecological cancers, such as triage tests for patients.Type: GrantFiled: April 17, 2015Date of Patent: April 9, 2019Assignee: Cedars-Sinai Medical CenterInventors: Sandra Orsulic, Beth Y. Karlan, Xiaojiang Cui, Mourad Tighiouart, Dong-Joo Cheon, Zhenqiu Liu
-
Publication number: 20180142305Abstract: In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of FOXC1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided. In other embodiments, methods for diagnosing metastatic breast cancer using the expression ratio of FOXC1/FOXA1 in a population of breast cancer tumor cells are provided. The methods also entail administering a treatment for metastatic breast cancer if the expression ratio of FOXC1/FOXA1 in the population of breast cancer tumor cells is elevated as compared to a control. Other embodiments provide methods for treating breast cancer with a proteasome inhibitor alone or in combination with a Wnt inhibitor in subjects with tumor cells expressing FOXC1 in a subject.Type: ApplicationFiled: June 8, 2017Publication date: May 24, 2018Inventors: Partha S Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20180066033Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: ApplicationFiled: November 17, 2017Publication date: March 8, 2018Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI
-
Patent number: 9850293Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: GrantFiled: April 4, 2015Date of Patent: December 26, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Lali K. Medina-Kauwe, Jessica Sims, Michael Taguaim, Chris Hanson, Xiaojiang Cui
-
Publication number: 20170108500Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: October 13, 2016Publication date: April 20, 2017Inventor: Xiaojiang Cui
-
Publication number: 20160145642Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.Type: ApplicationFiled: July 11, 2014Publication date: May 26, 2016Applicant: Cedars-Sinai Medical CenterInventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
-
Publication number: 20160060316Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: ApplicationFiled: April 4, 2015Publication date: March 3, 2016Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI
-
Publication number: 20150376712Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level.Type: ApplicationFiled: June 24, 2015Publication date: December 31, 2015Inventors: Partha Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20150322530Abstract: Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of ovarian cancers through generation of ovarian cancer disease signatures (OCDSs) that account for molecular heterogeneity present in gynecological cancers. An ovarian cancer fixed signature (OCFS) is described which relates to the core programming of disease development, in addition to an ovarian cancer stem cell (OCSC) signature. Development various disease signature, suggests personalized treatment strategies focused on molecular subtypes of gynecological cancers, such as triage tests for patients.Type: ApplicationFiled: April 17, 2015Publication date: November 12, 2015Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Sandra Orsulic, Beth Y. Karlan, Xiaojiang Cui, Mourad Tighiouart, Dong-Joo Cheon, Zhenqiu Liu
-
Patent number: 9074253Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.Type: GrantFiled: September 27, 2013Date of Patent: July 7, 2015Assignee: JOHN WAYNE CANCER INSTITUTEInventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20150071852Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: April 10, 2014Publication date: March 12, 2015Applicant: John Wayne Cancer InstituteInventor: Xiaojiang Cui
-
Publication number: 20140134626Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.Type: ApplicationFiled: September 27, 2013Publication date: May 15, 2014Applicant: JOHN WAYNE CANCER INSTITUTEInventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20120201752Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: February 3, 2012Publication date: August 9, 2012Inventor: Xiaojiang Cui
-
Publication number: 20110150979Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level.Type: ApplicationFiled: August 7, 2010Publication date: June 23, 2011Inventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang